Herein we provide the first report of a new method for the preparation of porous functional poly(styrene-co-divinylbenzene) monoliths by use of reversible addition–fragmentation chain transfer (RAFT) polymerization. The method, exemplified by styrene–divinylbenzene copolymerization in the presence of 2-cyano-2-propyl dodecyl trithiocarbonate, provides control over polymerization kinetics, monolith morphology and surface functionality. Kinetic studies of monolith formation show a period of slow copolymerization, with a rate similar to RAFT homopolymerization of styrene, followed by rapid copolymerization, with a rate similar to that observed in conventional styrene–divinylbenzene copolymerization. The time to onset of rapid polymerization (gelation) and the monolith morphology depend strongly on the RAFT agent concentration. The RAFT-synthesized monoliths show a modified morphology with smaller pores and polymer globules when compared to non-RAFT monoliths, but importantly retain good flow properties. Retention of the thiocarbonylthio group within the monolith structure in an active form for surface-functionalization of the polymeric monoliths is demonstrated by the successful RAFT “grafting from” polymerization of (4-vinylphenyl)boronic acid. These functional monoliths have potential applications in chromatography and flow chemistry.
Atovaquone-proguanil (Malarone®) is used for malaria prophylaxis and treatment. While the cytochrome bc1-inhibitor atovaquone has potent activity, proguanil’s action is attributed to its cyclization-metabolite, cycloguanil. Evidence suggests that proguanil has limited intrinsic activity, associated with mitochondrial-function. Here we demonstrate that proguanil, and cyclization-blocked analogue tBuPG, have potent, but slow-acting, in vitro anti-plasmodial activity. Activity is folate-metabolism and isoprenoid biosynthesis-independent. In yeast dihydroorotate dehydrogenase-expressing parasites, proguanil and tBuPG slow-action remains, while bc1-inhibitor activity switches from comparatively fast to slow-acting. Like proguanil, tBuPG has activity againstP. bergheiliver-stage parasites. Both analogues act synergistically with bc1-inhibitors against blood-stages in vitro, however cycloguanil antagonizes activity. Together, these data suggest that proguanil is a potent slow-acting anti-plasmodial agent, that bc1 is essential to parasite survival independent of dihydroorotate dehydrogenase-activity, that Malarone® is a triple-drug combination that includes antagonistic partners and that a cyclization-blocked proguanil may be a superior combination partner for bc1-inhibitors in vivo.
Vinylogous esters bearing para or metamethoxy benzyl groups undergo oxidative cyclisation with 5–20 mol% iodobenzene and m-CPBA to give spirofuran or benzopyran containing heterocycles. The reaction allows rapid generation of skeletal complexity in good to excellent yields via a novel oxidative cyclisation.